06 Apr New Therapeutic Horizons for Graves’ Hyperthyroidism
Graves’ hyperthyroidism is characterized by the presence of autoantibodies that stimulate the thy‐ roid-stimulating hormone receptor (TSHR), resulting in uncontrolled secretion of excessive thy‐ roid hormone. Conventional treatments, including antithyroid medication, radioiodine, or surgeryhave remained largely unchanged for the past 70 years and either lack efficacy for many patients,or result in lifelong thyroid hormone replacement therapy, in the case of the latter 2 options.
Sorry, the comment form is closed at this time.